Prestige BioPharma Limited (KRX:950210)
South Korea · Delayed Price · Currency is KRW 13,670
+290 (2.17%)
At close: Dec 5, 2025
Prestige BioPharma Revenue
Prestige BioPharma had revenue of 2.31B KRW in the quarter ending September 30, 2025, with 3.87% growth. This brings the company's revenue in the last twelve months to 14.41B, up 406.89% year-over-year. In the fiscal year ending June 30, 2025, Prestige BioPharma had annual revenue of 14.33B with 1,978.97% growth.
Revenue (ttm)
14.41B
Revenue Growth
+406.89%
P/S Ratio
11.40
Revenue / Employee
n/a
Employees
n/a
Market Cap
164.30B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 14.33B | 13.64B | 1,978.97% |
| Jun 30, 2024 | 689.08M | 527.23M | 325.77% |
| Jun 30, 2023 | 161.84M | - | - |
| Jun 30, 2022 | - | - | - |
| Jun 30, 2021 | - | - | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.50T |
| Celltrion | 3.90T |
| Yuhan | 2.14T |
| Hanmi Pharm. | 1.47T |
| SK Biopharmaceuticals | 675.41B |
| Sam Chun Dang Pharm. | 220.74B |
| ALTEOGEN | 202.18B |
| LigaChem Biosciences | 159.27B |